


Indimitecan

| | | | |
|--------------------|---|-------|----------|
| Cat. No.: | HY-18350 | | |
| CAS No.: | 915360-05-3 | | |
| Molecular Formula: | C ₂₅ H ₂₁ N ₃ O ₆ | | |
| Molecular Weight: | 459.45 | | |
| Target: | Topoisomerase | | |
| Pathway: | Cell Cycle/DNA Damage | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



SOLVENT & SOLUBILITY

In Vitro

DMSO : 8.33 mg/mL (18.13 mM; ultrasonic and warming and adjust pH to 3 with HCl and heat to 60°C)

| Solvent | Mass | Concentration | | |
|---------------------------|-------|---------------|------------|------------|
| | | 1 mg | 5 mg | 10 mg |
| Preparing Stock Solutions | 1 mM | 2.1765 mL | 10.8826 mL | 21.7652 mL |
| | 5 mM | 0.4353 mL | 2.1765 mL | 4.3530 mL |
| | 10 mM | 0.2177 mL | 1.0883 mL | 2.1765 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Indimitecan (LMP776) is a topoisomerase I (Top1) inhibitor with anticancer activities^[1].

IC₅₀ & Target

Top1

In Vitro

Indimitecan (LMP776) (0-100 μM) shows antiproliferative potencies against various human cancer cell lines, with mean-graph midpoint (MGM) of 0.079 ± 0.023 μM^[1].

Indimitecan shows potent DNA cleavage due to Top1 inhibition^[1].

Indimitecan can be substrates for metabolic ketone reductases^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line: HOP-62, HCT-116, SF-539, UACC-62, OVCAR-3, SN12C, DU-145, MCF-7

Concentration: 0-100 μM

| | |
|------------------|--|
| Incubation Time: | |
| Result: | Shown growth inhibition with GI ₅₀ s of <0.01, <0.01, 0.04, <0.01, 0.08, <0.01, <0.01 and 0.01 μM against HOP-62, HCT-116, SF-539, UACC-62, OVCAR-3, SN12C, DU-145 and MCF-7 cells, respectively. And the mean-graph midpoint (MGM) for growth inhibition of all human cancer cell lines successfully tested (the National Cancer Institute's developmental therapeutics assay (the "NCI60")) was 0.079 ± 0.023 μM. |

REFERENCES

[1]. Cinelli MA, et al. Identification, synthesis, and biological evaluation of metabolites of the experimental cancer treatment drugs indotecan (LMP400) and indimitecan (LMP776) and investigation of isomerically hydroxylated indenoisoquinoline analogues as to

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA